Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pulmonology

Decoding Your HRCT Scan, PFTs, and Biopsy Reports

At a Glance

Accurately diagnosing Interstitial Lung Disease (ILD) requires High-Resolution CT (HRCT) scans, Pulmonary Function Tests (PFTs) measuring FVC and DLCO, and sometimes a lung biopsy. A multidisciplinary review of these specific results is the gold standard for determining your exact ILD type.

Navigating medical reports can feel like reading a foreign language. However, understanding a few key terms in your HRCT (High-Resolution CT) and PFT (Pulmonary Function Test) reports can help you advocate for yourself and ensure your diagnosis is on the right track.

Decoding Your HRCT Scan Patterns

The HRCT is the most important imaging tool for ILD. Radiologists look for specific “patterns” of tissue damage that hint at the underlying cause [1]. Common patterns include:

  • UIP (Usual Interstitial Pneumonia): This pattern is the hallmark of Idiopathic Pulmonary Fibrosis (IPF). It is characterized by honeycombing (small clusters of cystic airspaces that look like a beehive) and traction bronchiectasis (airways that are pulled open and distorted by surrounding scar tissue) [2][3]. These changes usually happen at the very bottom and outer edges of the lungs [4].
  • NSIP (Non-Specific Interstitial Pneumonia): This pattern is often seen in autoimmune-related ILD. It is characterized by ground-glass opacities—a hazy, gray appearance on the scan that looks like looking through frosted glass [5]. A key clue for NSIP is subpleural sparing, where the very outer edge of the lung tissue remains clear while the tissue just inside it is affected [6].
  • Mosaic Attenuation: This pattern looks like a patchwork quilt of dark and light areas on the scan. It indicates “air trapping,” where air gets stuck in the lungs when you exhale. This is a classic warning sign of Hypersensitivity Pneumonitis (HP) [7].

Understanding Your Lung Function (PFTs)

Pulmonary Function Tests (PFTs) measure how well your lungs move air and transfer oxygen. Two numbers are particularly important:

  1. FVC (Forced Vital Capacity): This is the total amount of air you can exhale after taking the deepest breath possible. In ILD, the lungs become stiff, which reduces the “room” for air, causing the FVC to drop [8][9]. Doctors track this number over time; a decline in FVC is a primary sign that the disease is progressing [10][11].
  2. DLCO (Diffusing Capacity of the Lung for Carbon Monoxide): This measures how well oxygen travels from your air sacs into your blood. Because ILD thickens the “walls” between the air and the blood, the DLCO often drops [12]. In some cases, the DLCO may drop before the FVC, making it a sensitive early warning sign [13].

When Imaging Isn’t Enough: The Biopsy

If your scans and blood work don’t provide a clear answer, your team may suggest a lung biopsy to look at the tissue directly [14]. There are two main ways this is done:

  • Transbronchial Cryobiopsy (TBLC): A newer, less invasive option. A doctor passes a flexible tube down your throat while you are sedated and uses a freezing probe to take small samples. It is safer, has a shorter recovery time, and is often done as an outpatient procedure [15][16].
  • Surgical Lung Biopsy (VATS): This is a surgery performed by a thoracic surgeon using small incisions in the chest [17]. Important Risk: Biopsies are not just routine check-boxes. Surgical biopsies, in particular, carry the risk of triggering an Acute Exacerbation of your ILD [18][19]. The MDD team must carefully weigh whether the benefit of an exact diagnosis is worth the surgical risk for your specific body.

Your Diagnostic “Completeness Checklist”

Before settling on a final treatment plan, ensure your workup includes these “Gold Standard” components:

  • [ ] High-Resolution CT (HRCT) Scan: Specifically ordered as “high-resolution” to see the fine details of the interstitium [1].
  • [ ] Full PFTs with DLCO: Not just a simple handheld breath test, but a full evaluation in a specialized lab [8].
  • [ ] Autoimmune Serology Panel: Blood tests to look for markers of RA, Scleroderma, Lupus, or Sjogren’s [20][21].
  • [ ] Environmental History: A thorough review of any exposure to birds, mold, or workplace dusts [20].
  • [ ] Multidisciplinary Discussion (MDD): Confirmation that your case was reviewed by a team of specialists (Pulmonology, Radiology, and Pathology) [22][23].

Common questions in this guide

What does a UIP pattern with honeycombing mean on my HRCT scan?
A UIP pattern with honeycombing indicates severe scarring in the lungs that appears as small, cystic clusters on a scan. It is considered the classic hallmark sign of Idiopathic Pulmonary Fibrosis (IPF).
Why are my FVC and DLCO numbers important on a pulmonary function test?
FVC measures your total lung volume, which decreases as lungs become stiff from scarring. DLCO measures how well oxygen transfers into your blood, which drops as lung tissue thickens. Doctors track these numbers over time to monitor if your disease is progressing.
What is the difference between a cryobiopsy and a surgical lung biopsy?
A transbronchial cryobiopsy is a less invasive outpatient procedure that uses a freezing probe passed through the throat to collect lung tissue. A surgical lung biopsy requires incisions in the chest and carries higher risks, including the possibility of triggering an acute flare-up of your condition.
Why do I need a Multidisciplinary Discussion (MDD) for my lung diagnosis?
An MDD ensures your test results are jointly reviewed by a specialized team of pulmonologists, radiologists, and pathologists. This collaborative review is the gold standard for accurately diagnosing interstitial lung disease before finalizing any treatment plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my HRCT scan show 'honeycombing' or 'subpleural sparing'? What does that mean for my specific diagnosis?
  2. 2.What were my FVC and DLCO percentages, and how do they compare to my last test?
  3. 3.Based on my imaging and blood work, how certain are you of the diagnosis? Is an MDD review or a biopsy the next logical step?
  4. 4.If a biopsy is needed, am I a candidate for a transbronchial cryobiopsy, or is a surgical biopsy (VATS) preferred for my case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Updates in the New Guidelines for Idiopathic Pulmonary Fibrosis: Role of Cryobiopsy.

    Cascante Rodrigo JA, Cebollero Rivas P

    Open respiratory archives 2023; (5(1)):100226 doi:10.1016/j.opresp.2022.100226.

    PMID: 37497249
  2. 2

    Tissue Continues to Be the Issue: Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases.

    Raparia K, Raj R

    Archives of pathology & laboratory medicine 2019; (143(1)):30-33 doi:10.5858/arpa.2018-0134-RA.

    PMID: 30785335
  3. 3

    Current State of Fibrotic Interstitial Lung Disease Imaging.

    Chelala L, Brixey AG, Hobbs SB, et al.

    Radiology 2025; (316(1)):e242531 doi:10.1148/radiol.242531.

    PMID: 40590695
  4. 4

    Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings.

    Iwasawa T, Takemura T, Ogura T

    Japanese journal of radiology 2018; (36(3)):165-180 doi:10.1007/s11604-017-0713-0.

    PMID: 29247372
  5. 5

    The role of vascularity and the fibrovascular interface in interstitial lung diseases.

    Dietrich J, Kang A, Tielemans B, et al.

    European respiratory review : an official journal of the European Respiratory Society 2025; (34(175)) doi:10.1183/16000617.0080-2024.

    PMID: 39909504
  6. 6

    Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP).

    Hino T, Lee KS, Yoo H, et al.

    European journal of radiology open 2021; (8()):100336 doi:10.1016/j.ejro.2021.100336.

    PMID: 33796637
  7. 7

    Mosaic attenuation in non-fibrotic areas as a predictor of non-usual interstitial pneumonia pathologic diagnosis.

    Gayá García-Manso I, Arenas-Jiménez J, García-Sevila R, et al.

    Scientific reports 2022; (12(1)):7289 doi:10.1038/s41598-022-10750-7.

    PMID: 35508493
  8. 8

    Clinical characteristics of non-idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases: A single-center retrospective study.

    Komatsu M, Yamamoto H, Kitaguchi Y, et al.

    Medicine 2021; (100(13)):e25322 doi:10.1097/MD.0000000000025322.

    PMID: 33787626
  9. 9

    Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.

    Maher TM, Stowasser S, Voss F, et al.

    Respirology (Carlton, Vic.) 2023; (28(12)):1147-1153 doi:10.1111/resp.14579.

    PMID: 37646126
  10. 10

    Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

    Wells AU, Flaherty KR, Brown KK, et al.

    The Lancet. Respiratory medicine 2020; (8(5)):453-460 doi:10.1016/S2213-2600(20)30036-9.

    PMID: 32145830
  11. 11

    Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.

    Matteson EL, Aringer M, Burmester GR, et al.

    Clinical rheumatology 2023; (42(9)):2311-2319 doi:10.1007/s10067-023-06623-7.

    PMID: 37209188
  12. 12

    Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.

    Caron M, Hoa S, Hudson M, et al.

    European respiratory review : an official journal of the European Respiratory Society 2018; (27(148)) doi:10.1183/16000617.0102-2017.

    PMID: 29769294
  13. 13

    Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.

    Le Gouellec N, Duhamel A, Perez T, et al.

    PloS one 2017; (12(8)):e0181692 doi:10.1371/journal.pone.0181692.

    PMID: 28763468
  14. 14

    Transbronchial Lung Cryobiopsy in Interstitial Lung Diseases: Best Practice.

    Colella S, Haentschel M, Shah P, et al.

    Respiration; international review of thoracic diseases 2018; (95(6)):383-391 doi:10.1159/000488910.

    PMID: 29894993
  15. 15

    Diagnostic yield and safety of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases: a systematic review and meta-analysis.

    Rodrigues I, Estêvão Gomes R, Coutinho LM, et al.

    European respiratory review : an official journal of the European Respiratory Society 2022; (31(166)) doi:10.1183/16000617.0280-2021.

    PMID: 36198419
  16. 16

    Transbronchial Cryobiopsy in the Diagnosis of Fibrotic Interstitial Lung Disease.

    Mehrad M, Colby TV, Rossi G, Cavazza A

    Archives of pathology & laboratory medicine 2020; (144(12)):1501-1508 doi:10.5858/arpa.2020-0007-RA.

    PMID: 32320274
  17. 17

    Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial.

    Kalverda KA, Ninaber MK, Wijmans L, et al.

    The Lancet. Respiratory medicine 2024; (12(7)):513-522 doi:10.1016/S2213-2600(24)00074-2.

    PMID: 38640934
  18. 18

    In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011.

    Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB

    American journal of respiratory and critical care medicine 2016; (193(10)):1161-7 doi:10.1164/rccm.201508-1632OC.

    PMID: 26646481
  19. 19

    Clinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center.

    Le Guen P, Iquille J, Debray MP, et al.

    The Annals of thoracic surgery 2022; (114(3)):1022-1028 doi:10.1016/j.athoracsur.2021.07.038.

    PMID: 34403693
  20. 20

    An update on interstitial lung disease.

    Mudawi D, Heyes K, Hastings R, et al.

    British journal of hospital medicine (London, England : 2005) 2021; (82(7)):1-14 doi:10.12968/hmed.2020.0556.

    PMID: 34338019
  21. 21

    Proteomics: Potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease.

    Wu Y, Li Y, Luo Y, et al.

    Frontiers in immunology 2023; (14()):1146904 doi:10.3389/fimmu.2023.1146904.

    PMID: 37063894
  22. 22

    Interstitial Lung Disease in India. Results of a Prospective Registry.

    Singh S, Collins BF, Sharma BB, et al.

    American journal of respiratory and critical care medicine 2017; (195(6)):801-813 doi:10.1164/rccm.201607-1484OC.

    PMID: 27684041
  23. 23

    Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases: A Retrospective Observational Study of 938 Cases.

    De Sadeleer LJ, Meert C, Yserbyt J, et al.

    Chest 2018; (153(6)):1416-1423 doi:10.1016/j.chest.2018.03.026.

    PMID: 29608882

This page explains interstitial lung disease (ILD) diagnostic tests for educational purposes only. Always consult your pulmonologist or multidisciplinary care team for professional interpretation of your specific HRCT, PFT, and biopsy reports.

Get notified when new evidence is published on Interstitial lung disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.